Paper Details

  1. Home
  2. Paper Details

LOSS OF EFFICACY OF ADALIMUMAB IN HIDRADENITIS SUPPURATIVA: FOCUS ON ALTERNATIVES.

Author: TchernevG

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Adalimumab, a commonly used biologic for hidradenitis suppurativa (HS), often loses efficacy, leading to treatment resistance. This case report describes a patient with HS who achieved long-term remission after surgical deroofing, suggesting that surgery may be a viable alternative or adjunct to biological therapy in cases of adalimumab failure.
Paper Details　
Original Abstract of the Article :
The loss of efficacy of adalimumab, one of the most commonly used biologics for the treatment of hidradenitis suppurativa/acne inversa, is not news to the scientific community, and it should be noted that the number of cases not responding to this agent has been progressively increasing in recent ye...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/37805915

データ提供：米国国立医学図書館（NLM）

Hidradenitis Suppurativa: Exploring New Horizons

The desert of hidradenitis suppurativa (HS) is a challenging one for patients, with chronic inflammation and painful lesions often taking a heavy toll. This study explores the loss of efficacy of adalimumab, a commonly used biologic for HS, and delves into potential alternative treatment options. The authors highlight the complexities of HS management and the need for a personalized approach to address the unique needs of each patient.

A Shifting Landscape

The study reveals the ongoing challenge of managing HS, with the loss of efficacy of adalimumab becoming increasingly prevalent. The authors discuss the need for alternative treatments, including other biologics and surgical interventions, as patients develop resistance to adalimumab. It's like navigating a desert landscape where the oases we once relied upon are drying up, forcing us to seek new sources of relief.

The Search for New Oases

This research emphasizes the importance of exploring new treatment options for HS, particularly in patients who have lost responsiveness to adalimumab. The authors advocate for a multifaceted approach that includes surgical deroofing, other biologics, and careful monitoring of patient response. It's like searching for a new oasis in the desert, where the journey is filled with challenges but the rewards are great.

Dr.Camel's Conclusion

This study provides valuable insights into the ongoing challenges and evolving treatment landscape of hidradenitis suppurativa. It's a reminder that the desert of HS is a dynamic one, requiring a persistent and creative approach to find new sources of relief for patients.

Date :
  1. Date Completed 2023-11-02
  2. Date Revised 2023-11-02
Further Info :

Pubmed ID

37805915

DOI: Digital Object Identifier

37805915

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.